All stock lists
Spyre Therapeutics, Inc. (NASDAQ:SYRE)
US · Delayed Price · Currency is USD
Healthcare · Biotechnology
90.33-2.00 (-2.17%)
Insider Score
––Not scored
SYRE Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
SYRE analyst forecast
SYRE analyst consensus
Moderate Buy6 ratings
Buy 5 Hold 1 Sell 0
Based on each firm’s most recent rating in the last 3 months — one vote per firm, so a desk that reiterates weekly does not count three times.
SYRE 12-month price target
$123.00+32.8% upsideaverage of 2 firms
$130.00High
$116.00Low
Best analysts covering SYRE
- BTIG50%success rate · 2 calls
- Stifel50%success rate · 2 calls
- Wells Fargo0%success rate · 2 calls
- Guggenheim0%success rate · 1 call
Measured by us from each firm’s own rating dates and this stock’s split- and dividend-adjusted closes. How we calculate this.
SYRE analyst ratings
| Firm | Price target | Action | ||||
|---|---|---|---|---|---|---|
| — | BTIG | Buy | — | — | Reiterated | 2026-10-19 |
| — | BTIG | Buy | — | — | Reiterated | 2026-10-01 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-09-09 |
| Robert W. Baird | — | $116.00 | +27.8% | — | 2026-09-09 | |
| — | BTIG | Buy | — | — | Reiterated | 2026-09-08 |
| Guggenheim | — | $130.00 | +38.9% | — | 2026-08-27 | |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-08-26 |
| — | Deutsche Bank | Buy | — | — | Reiterated | 2026-08-26 |
| — | BTIG | Buy | — | — | Reiterated | 2026-08-26 |
| — | BTIG | Buy | — | — | Reiterated | 2026-08-11 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-08-05 |
| — | Guggenheim | Buy | — | — | Reiterated | 2026-08-05 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-08-05 |
| — | Wolfe Research | Peer Perform | — | — | Downgraded | 2026-07-28 |
| — | Mizuho | Outperform | — | — | Reiterated | 2026-07-13 |
| — | Deutsche Bank | Buy | — | — | Reiterated | 2026-06-23 |
| — | BTIG | Buy | — | — | Reiterated | 2026-06-15 |
| — | Deutsche Bank | Buy | — | — | Reiterated | 2026-06-04 |
| — | Citigroup | Buy | — | — | Reiterated | 2026-05-06 |
| — | Stifel | Buy | — | — | Reiterated | 2026-05-06 |
| — | Jones Trading | Buy | — | — | Reiterated | 2026-04-17 |
| — | Wedbush | Outperform | — | — | Reiterated | 2026-04-14 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-04-14 |
| — | Baird | Outperform | — | — | Reiterated | 2026-04-14 |
| — | Deutsche Bank | Buy | — | — | Reiterated | 2026-04-14 |
| — | Leerink Partners | Outperform | — | — | Reiterated | 2026-04-13 |
| — | Jefferies | Buy | — | — | Reiterated | 2026-04-13 |
| — | BTIG | Buy | — | — | Reiterated | 2026-04-13 |
| — | BTIG | Buy | — | — | Reiterated | 2026-03-31 |
| — | Stifel | Buy | — | — | Reiterated | 2026-03-18 |
| — | BTIG | Buy | — | — | Reiterated | 2026-03-16 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2026-02-20 |
| — | BTIG | Buy | — | — | Reiterated | 2026-02-20 |
| — | BTIG | Buy | — | — | Reiterated | 2026-01-16 |
| — | Jones Trading | Buy | — | — | Upgraded | 2025-12-01 |
| — | BTIG | Buy | — | — | Reiterated | 2025-09-16 |
| — | Baird | Outperform | — | — | Reiterated | 2024-11-13 |
| — | Guggenheim | Buy | — | — | Reiterated | 2024-10-25 |
| — | Wells Fargo | Overweight | — | — | Reiterated | 2024-05-13 |
| — | BTIG | Buy | — | — | Reiterated | 2024-05-10 |
| — | Stifel | Buy | — | — | Reiterated | 2024-03-26 |
| — | Wells Fargo | Overweight | — | — | Upgraded | 2024-03-01 |
| — | Stifel | Buy | — | — | Reiterated | 2023-12-18 |
SYRE earnings vs. estimates
| Quarter | EPS est. | EPS actual | Revenue est. | Revenue actual |
|---|---|---|---|---|
| 2026-02-19 | -0.66 | -0.70 | $142.9M | $90.5M |
| 2026-05-05 | -0.66 | -0.74 | $0 | $0 |
| 2026-08-04 | -0.76 | -0.36 | $0 | $0 |
| 2026-11-03 | -0.78 | 0.00 | $0 | $0 |
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.